Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Limosilactobacillus fermentum PS150
- Development stage
- Unknown
- Lead developer
- Bened Biomedical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
PS150 is a psychobiotic probiotic strain of *Limosilactobacillus fermentum* (formerly *Lactobacillus fermentum*) developed by the Taiwan-based company Bened Biomedical. It functions through the gut-brain axis to address sleep disorders and emotional health. The strain's mechanism of action involves the regulation of sleep-related neurotransmitters, specifically by increasing gamma-aminobutyric acid (GABA) levels in the cerebral cortex and inhibiting wake-promoting orexinergic neurons. Research indicates that exopolysaccharides (EPS) produced by PS150 are key effectors responsible for its hypnotic and sedative effects. PS150 has demonstrated efficacy in both live and heat-killed (HT-PS150) forms in preclinical models and is currently undergoing clinical trials for sleep improvement in healthy populations. It received the 22nd National Innovation Award in Taiwan in December 2025.
- Other names
- Lactobacillus fermentum PS150
02
Targets
GABA-B (Gamma-aminobutyric acid receptor type B)HCRTR1 (Orexin/hypocretin receptor type 1)
Beyond the preview
Go deeper on Limosilactobacillus fermentum PS150.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Limosilactobacillus fermentum PS150.